Search Results for:

133  0

Gilead Subsidiary to Launch Authorized Generics of Epclusa and Harvoni

Gilead Sciences, Inc. announced plans to launch authorized generic versions of Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni® (ledipasvir 90mg/sofosbuvir 400mg), Gilead’s leading treatments for chronic hepatitis C virus (HCV), in the United States, through a newly created subsidiary, Asegua Therapeutics LLC. The authorized generics will ...

September 25, 2018
312  0

GNP+ Announces Search for Executive Director

The Global Network of People Living with HIV (GNP+) is searching for a skilled and passionate leader and manager to lead its organization in the implementation of an exciting and ambitious strategic plan.

September 18, 2018